Aidoc Medical Ltd. raises $150M in Series C

Aidoc Medical Ltd. has raised $150 million in a Series C funding round led by Goldman Sachs, bolstering the company's ability to advance its AI-driven diagnostic platform. Additionally, Nvidia’s NVentures, General Catalyst, and SoftBank Investment Advisors participated in the round. This latest influx of capital brings Aidoc's total external funding to over $500 million, propelling its efforts to enhance the efficiency of medical diagnostics through artificial intelligence.

Aidoc's platform, known as aiOS, leverages a proprietary Clinical AI Reasoning Engine (CARE) to streamline the diagnostic process for healthcare providers by analyzing a variety of medical data inputs, including images, patient vitals, and lab results. Notably, the U.S. Food and Drug Administration recently approved the CARE model for use across 11 disease indicators, underscoring its capability to deliver precise diagnoses with a specificity of up to 99.7%. The technical prowess of the platform lies in its ability to detect incidental findings in scans and prioritize them by urgency through a mobile app interface.

The fresh capital is earmarked for expanding the international reach of aiOS and enhancing the CARE model to recognize additional disease markers. Aidoc is also developing functionality to automate the drafting of clinical reports from medical images, further integrating its platform into the operational workflow of hospitals. Currently, the aiOS system is utilized in approximately 2,000 hospitals worldwide, processing data for over 60 million patients each year.

Aidoc’s competitive edge in a burgeoning medical AI sector rests on its CARE model's accuracy and comprehensiveness, setting it apart from other single-data AI models. The field is increasingly crowded as firms channel resources into AI for healthcare to expedite diagnostics and improve patient care. Aidoc's push to scale is occurring in a landscape where venture capital continues to fuel innovation despite a more cautious funding environment.

Looking forward, Aidoc aims to sustain its growth momentum by deepening market penetration and continuously refining its product suite. Regulatory progress will remain critical, as obtaining clearance for additional functionalities will expand use cases for aiOS. The successful integration of its new offerings into hospital systems could solidify its position in the competitive medical AI market.